O-GlcNAcylation ameliorates the pathological manifestations of Alzheimer's disease by inhibiting necroptosis
journal contributionposted on 08.03.2021, 05:15 by J Park, HJ Ha, ES Chung, SH Baek, Y Cho, HK Kim, J Han, JH Sul, J Lee, E Kim, J Kim, YR Yang, M Park, SH Kim, Thiruma ArumugamThiruma Arumugam, H Jang, SW Seo, PG Suh, DG Jo
© 2021 American Association for the Advancement of Science. All rights reserved. O-GlcNAcylation (O-linked β-N-acetylglucosaminylation) is notably decreased in Alzheimer's disease (AD) brain. Necroptosis is activated in AD brain and is positively correlated with neuroinflammation and tau pathology. However, the links among altered O-GlcNAcylation, β-amyloid (Aβ) accumulation, and necroptosis are unclear. Here, we found that O-GlcNAcylation plays a protective role in AD by inhibiting necroptosis. Necroptosis was increased in AD patients and AD mouse model compared with controls; however, decreased necroptosis due to O-GlcNAcylation of RIPK3 (receptor-interacting serine/threonine protein kinase 3) was observed in 5xFAD mice with insufficient O-linked β-N-acetylglucosaminase. O-GlcNAcylation of RIPK3 suppresses phosphorylation of RIPK3 and its interaction with RIPK1. Moreover, increased O-GlcNAcylation ameliorated AD pathology, including Aβ burden, neuronal loss, neuroinflammation, and damaged mitochondria and recovered the M2 phenotype and phagocytic activity of microglia. Thus, our data establish the influence of O-GlcNAcylation on Aβ accumulation and neurodegeneration, suggesting O-GlcNAcylation-based treatments as potential interventions for AD.